View Older Stories View More Recent Stories

Jun 12, 2025 09:00AM Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
Jun 11, 2025 07:02AM Ionis Pharmaceuticals (IONS): First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
Jun 11, 2025 07:00AM First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome
May 19, 2025 07:01AM Ionis Pharmaceuticals (IONS) announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 19, 2025 07:00AM Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides
May 6, 2025 07:05AM Ionis to host 2025 virtual Annual Meeting of Stockholders
Apr 30, 2025 07:00AM Ionis reports first quarter 2025 financial results
Apr 29, 2025 07:00AM New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies
Apr 16, 2025 07:05AM Ionis to hold first quarter 2025 financial results webcast
Apr 3, 2025 07:05AM Ionis to host expert panel discussion on sHTG
Mar 31, 2025 07:05AM Ionis to present at upcoming investor conferences
Mar 26, 2025 07:02AM Ionis Pharmaceuticals (IONS) expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 26, 2025 07:00AM Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.
Mar 11, 2025 06:13PM Ionis Pharmaceuticals (IONS) and Ono announce global license agreement
Mar 11, 2025 06:00PM Ionis and Ono announce global license agreement for sapablursen in polycythemia vera
Mar 10, 2025 07:02AM Ionis Pharmaceuticals (IONS) Announces WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Mar 10, 2025 07:00AM WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy
Feb 25, 2025 07:05AM Ionis to present at upcoming investor conferences
Feb 20, 2025 07:03AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at AAAAI/WAO
Feb 20, 2025 07:00AM New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control
Feb 19, 2025 07:00AM Ionis reports fourth quarter and full year 2024 financial results
Feb 5, 2025 07:05AM Ionis to hold fourth quarter and full year 2024 financial results webcast
Jan 13, 2025 08:00AM Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum
Jan 8, 2025 04:11PM Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference
Dec 19, 2024 06:30PM Ionis Pharmaceuticals (IONS) FDA approves TRYNGOLZA for adults with familial chylomicronemia syndrome
Dec 19, 2024 06:28PM TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
Nov 7, 2024 07:05AM Ionis to present at upcoming investor conferences
Nov 6, 2024 07:01AM Ionis Pharmaceuticals (IONS) Announces Pivotal Phase 3 Trial Design for ION582
Nov 6, 2024 07:01AM Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Nov 6, 2024 07:00AM Ionis reports third quarter 2024 financial results
Nov 4, 2024 09:45AM Ionis Pharmaceuticals (IONS) announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Nov 4, 2024 09:44AM Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
Oct 23, 2024 07:05AM Ionis to hold third quarter 2024 financial results webcast
Oct 21, 2024 05:57AM Ionis Pharmaceuticals (IONS) reports WAINZUA recommended for approval in the EU by CHMP
Oct 21, 2024 02:08AM WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Oct 3, 2024 07:01AM Ionis Pharmaceuticals (IONS): New positive donidalorsen data to be presented at ACAAI
Oct 3, 2024 07:00AM New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
Oct 1, 2024 07:01AM Ionis Pharmaceuticals (IONS): Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Oct 1, 2024 07:00AM Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
Sep 4, 2024 08:00AM Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Aug 28, 2024 07:05AM Ionis to present at upcoming investor conferences
Aug 1, 2024 07:00AM Ionis reports second quarter 2024 financial results
Jul 22, 2024 07:03AM Ionis Pharmaceuticals (IONS) announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 22, 2024 07:00AM Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome
Jul 19, 2024 08:24AM Ionis to hold second quarter 2024 financial results webcast
Jul 18, 2024 07:00AM Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease
Jul 8, 2024 07:05AM Ionis announces webcast to report HALOS study results for ION582 in Angelman syndrome
Jun 25, 2024 06:55AM Ionis Pharmaceuticals (IONS) announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 25, 2024 06:55AM Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
Jun 18, 2024 07:04AM Ionis Pharmaceuticals (IONS) expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
View More Recent Stories View Older Stories